Extrapyramidal syndromes in neuroleptic-treated patients: Prevalence, risk factors, and association with tardive dyskinesia

Journal of Clinical Psychopharmacology

Volumn 19, Issue 3, 1999, Pages 203-208

  Muscettola, Giovanni ^a   Barbato, Giuseppe ^b   Pampallona, Sandro ^c   Casiello, Margherita ^a   Bollini, Paola ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c ForMed   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; AKATHISIA; ARTICLE; BRADYKINESIA; DRUG EFFICACY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MULTIVARIATE ANALYSIS; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RIGIDITY; RISK FACTOR; TARDIVE DYSKINESIA; TREMOR;

ADOLESCENT; ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 0032960326     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199906000-00002     Document Type: Article

References (43)

1. Casey DE, Keepers GA. Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. In: Casey DE, Vibeke Christensen A, eds. Psychopharmacology: current trends. Berlin: Springer, 1988:74-93.
2. Freyhan FA. Psychomotility and parkinsonism in treatment with neuroleptic drugs. Arch Neurol Psychiatry 1957;78:465-72.
3. Haase HJ. Extrapyramidal modification of fine movements: a "conditio sine qua non" of fundamental therapeutic action of neuroleptic drugs. Rev Can Biol 1961;20:425-49.
4. Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991;4:109-20.
5. Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175:1054-60.
6. Ayd FJ. Early-onset neuroleptic-induced extrapyramidal reactions. A second survey, 1961-1982. In: Coyle JT, Enna SJ, eds. Neuroleptics: neurochemical, behavioral and clinical perspective. New York: Raven Press, 1983:75-92.
7. Yadalam KG. Drug-induced parkinsonism. In: Kehawan MS, Kennedy JS, eds. Drug-induced dysfunction in psychiatry. New York: Hemisphere Publishing Corporation, 1993:119-27.
8. Hollister LE. Clinical pharmacology of psychotherapeutic drugs. New York: Churchill Livingstone, 1983.
9. Simpson GM, Angus JWS. Drug-induced extrapyramidal disorder. Acta Psychiatr Scand Suppl 1970;212:1-58.
10. Glick ID, Jacobs M, Lieberman J, Simpson G, Schooler N. Prediction of short-term outcome in schizophrenia: depressive symptoms, negative symptoms and extrapyramidal signs. Psychopharmacol Bull 1989;25:344-7.
11. Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. Department of Health, Education and Welfare, 1976.
12. Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia (RD-TD). Arch Gen Psychiatry 1982;39:486-7.
13. Muscettola G, Casiello M, Barbato G. Tardive dyskinesia in neuroleptic-treated patients: a prevalence survey in Italy. Key Biscane, FL: New Clinical Drug Evaluation Unit Meeting, 1986.
14. Fleiss J. Statistical analysis of rates and proportions. 2nd ed. New York: Wiley, 1981.
15. Schlesselman JJ. Case-control studies. New York: Oxford University Press, 1982.
16. StataCorp. Stata statistical software release 50. College Station, TX: Stata Corporation, 1997.
17. Muscettola G, Pampallona S, Barbato G, Casiello M, Bollini P. Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiatr Scand 1993;87:29-36.
18. Toenniessen LM, Casey DE, McFarland BM. Tardive dyskinesia in the aged: duration of treatment relationships. Arch Gen Psychiatry 1985;42:278-84.
19. Binder RL, Kazamatsuri H, Nishimura T, McNiel DE. Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan. Am J Psychiatry 1987;144:1494-6.
20. Richardson MA, Craig TJ. The coexistence of parkinsonism-like symptoms and tardive dyskinesia. Am J Psychiatry 1982;139:341-3.
21. McCreadie RG, Robertson LJ, Wiles DH. The Nithsdale schizophrenia surveys. IX: akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels. Br J Psychiatry 1992;161:793-9.
22. Muscettola G. Epidemiologia degli interventi terapeutici e dei rischi dei trattamenti neurolettici. In: Progetto finalizzato CNR "medicina preventiva e riabilitativa." Roma: CNR, 1986:114-6.
23. Muscettola G, Casiello M, Bollini P, Sebastiani G, Pampallona S, Tognoni G. Pattern of therapeutic intervention and role of psychiatric settings: a survey in two regions of Italy. Acta Psychiatr Scand 1987;75:55-61.
24. Muscettola G, Bollini P, Pampallona S. Pattern of neuroleptic drug use in Italian mental health services. DICP 1991;25:296-301.
25. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45:79-91.
26. McGeer PL, McGeer EG. Aging and extrapyramidal function. Arch Neurol 1977;34:33-5.
27. Morgenstern H, Glazer WM, Niedzwiecki D, Nourjah P. The impact of neuroleptic medication on tardive dyskinesia: a metaanalysis of published studies. Am J Public Health 1987;77:717-24.
28. Khot V, Wyatt RJ. Not all that moves is tardive dyskinesia. Am J Psychiatry 1991;148:661-6.
29. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988;51:850-4.
30. Malhotra AK, Litman RE, Pickar D. Adverse effects of antipsychotic drugs. Drug Saf 1993;9:429-36.
31. Whitworth AB, Fleischaker WW. Adverse effects of antipsychotic drugs. Int Clin Psychopharmacol 1995;9[suppl 5]:21-7.
32. Opler LA. Drug treatment of schizophrenia: old issues and new developments. Einstein Q J Biol Med 1991;9:10-4.
33. Muscettola G, Barbato G, de Bartolomeis A, Monteleone P, Pickar D. Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia. Psychiatry Res 1990;33:259-67.
34. Fiorini A, Lo Russo L, Melega V. Reform said or done? The case of Emilia Romagna within the Italian psychiatric context. Am J Psychiatry 1997;154:94-8.
35. Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B, Borenstein M. Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull 1984;20:387-9.
36. De Fraites EG, Davis KL, Berger PA. Coexisting tardive dyskinesia and parkinsonism: a case report. Biol Psychiatry 1977;12: 267-72.
37. Bitton V, Melamed E. Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy. J Clin Psychiatry 1984;45:28-30.
38. Crane GE. Tardive dyskinesia and related neurological disorders. In: Inverssen LL, Inverssen SD, Snyder SN, eds. Handbook of psychopharmacology, vol 10. New York: Plenum Press, 1978:165-96.
39. Gerlach J, Korsgaard S. Classification of abnormal involuntary movements in psychiatric patients. Neuropsychiatr Clin 1983;2: 201-8.
40. Klawans HL. The pharmacology of tardive dyskinesia. Am J Psychiatry 1973;130:82-6.
41. Baldessarini RJ. Dopamine and the pathophysiology of dyskinesia induced by antipsychotic drugs. Annu Rev Neurosci 1980;3: 23-41.
42. Klawans H, Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry 1974;27:941-5.
43. Greil W, Haag H, Rossnagl G, Ruther E. Effect of anticholinergics on tardive dyskinesia: a controlled discontinuation study. Br J Psychiatry 1984;145:304-10.